Patricia Jakel, MN, RN, AOCN, emphasized that the bond oncology nurses have with patients with cancer necessitates honest and ...

A recent study found that toxicity is routinely minimized in phase 3 oncology trials, especially those that are not industry sponsored.

Staying up to date with data from trials and information from organizations dedicated to cancer research is crucial for ...

Although participants in the study had greater rates of nonadherence postintervention, those who reported nonadherence at ...

Panitumumab plus ipilimumab and nivolumab signaled complete or partial response in 18 patients with KRAS/NRAS/BRAF wild-type MSS mCRC at the 12-week mark. The addition of ipilimumab (Yervoy) and ...

Real-World Data Back First-Line Avelumab and Axitinib in Advanced RCC ...

Oncology nurses and APPs play a key role in educating patients on BREAKWATER study findings and their impact on BRAF-mutant ...

What multidisciplinary strategies have you found effective in managing the range of side effects associated with ALK inhibitors?

In your experience, how does lorlatinib’s side effect profile compare to other ALK inhibitors? Are there unique challenges or benefits with lorlatinib?

And again, it's very important that we educate the population. And when nurses are educated on the different subtypes of breast cancer, then we can also—we feel empowered. And now we can empower the ...

One of the hardest lessons learned occurred after I inadvertently failed at communication and education before transferring a ...